AI News Reports Rentosertib Is Moving Into Phase III IPF Trials

Insilico Medicine's AI-discovered rentosertib is moving into Phase III testing for idiopathic pulmonary fibrosis, giving the AI drug-discovery sector a later-stage clinical test rather than another platform claim.

AI News reported that the oral drug targets IPF, a lung-scarring disease, and that the programme has already passed target discovery, molecular design, preclinical validation, Phase I safety and randomised Phase IIa data.

The evidence is still clinical-stage evidence, not approval evidence.

The source said the Phase III trial will test whether the generative discovery workflow can produce efficacy in humans after earlier safety and lung-function results.

Phase IIa Data Covered 71 Patients At 22 Chinese Sites

The randomised Phase IIa trial evaluated 71 patients across 22 Chinese clinical sites, according to AI News.

Investigators tested 30 mg and 60 mg daily doses over a 12-week observation period and compared them with placebo.

The strongest disclosed result came from the 60 mg once-daily group.

AI News said those patients recorded a mean forced vital capacity gain of +98.4 mL, while the placebo group recorded a 20.3 mL loss.

The article said safety remained manageable, with adverse events mirroring expected baseline rates across trial arms.

The article also said the U.S. Food and Drug Administration granted Orphan Drug Designation to the asset in February 2023.

That designation does not approve the drug, but it records that the programme is recognised for a rare-disease development pathway.

Pharma.AI Pipeline Picked TNIK And Designed The Molecule

The source described rentosertib as a product of Insilico's Pharma.AI pipeline.

It said PandaOmics handled target discovery by processing genomics, clinical-trial outcomes, academic literature and patent intelligence, then identifying TNIK as the primary biological target for IPF intervention.

The Chemistry42 engine followed with generative molecular design rather than a search through existing compound libraries, AI News reported.

The article said the computational stage synthesised 79 physical molecules and that the team selected the 55th iteration for preclinical testing.

Insilico's cited development timeline is one of the article's clearest operational claims.

The process reduced the time from project initiation to preclinical candidate nomination to 18 months, according to the report.

That claim remains company-linked platform evidence until Phase III efficacy data and regulator decisions are public.

Peer-Reviewed Trail Includes Nature Biotechnology And Nature Medicine

AI News reported that Nature Biotechnology published the full discovery-to-clinic progression, including algorithmic TNIK target prioritisation, generative chemistry outputs, preclinical efficacy data and Phase I pharmacokinetics.

The article also said the Journal of Medicinal Chemistry published structural-biology validation for TNIK inhibitor chemotypes.

Nature Medicine documented the Phase IIa safety and lung-function data, according to the report.

AI News also cited Aging and Disease research that confirmed senomorphic activity from pharmacological TNIK inhibition, with reductions in extracellular matrix remodelling indicators.

That publication trail gives the programme more public evidence than a vendor product announcement, but it does not replace the Phase III efficacy readout.

Insilico CEO Alex Zhavoronkov said the programme had advanced through target discovery, molecular design, preclinical validation, Phase I safety, randomised Phase IIa data and into Phase III development.

The company did not disclose Phase III enrolment size, trial completion timing, regulatory filing dates, partner economics or any approval timetable.